{
    "nct_id": "NCT04495621",
    "official_title": "Open-label, Multicentre, Phase Ib/II Study of MEN1611, a PI3K Inhibitor, and Cetuximab in Patients With PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, 5-FU and Anti-EGFR Containing Regimens",
    "inclusion_criteria": "* Histological documentation of adenocarcinoma of the colon or rectum.\n* Progression or recurrence following prior irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens for metastatic disease.\n* Best response according to Response Evaluation Criteria in Solid Tumours criteria to the last anti-EGFR containing regimen of partial response or stable disease for at least 4 months.\n* Measurable disease according to RECIST criteria.\n* N-K-RAS (exons 2, 3 and 4) and BRAF wild-type and PIK3CA mutated.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous treatment with PI3K inhibitor.\n* Brain metastases, unless treated > 4 weeks before Screening Visit and only if clinically stable and not receiving corticosteroids.\n* NCI CTCAE v5.0 Grade â‰¥ 2 diarrhoea.\n* History of significant, uncontrolled or active cardiovascular disease.\n* Known active or uncontrolled pulmonary dysfunction.\n* Uncontrolled diabetes mellitus (HbA1c > 7%) and fasting plasma glucose > 126 mg/dL.\n* Known history of human immunodeficiency virus infection or active infection with hepatitis C virus or hepatitis B virus.\n* Concurrent chronic immunosuppressive treatment either with steroids or other immunosuppressive agents.",
    "miscellaneous_criteria": "Main"
}